See the DrugPatentWatch profile for polivy
Polyvaccine (Polivy) Clinical Trials: Understanding the Typical Age Range
Introduction
Polyvaccine, also known as Polivy, is a monoclonal antibody treatment used to treat certain types of non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL). Developed by AbbVie, Polivy has shown promising results in clinical trials, but what about its typical age range in these trials? In this article, we'll delve into the age demographics of Polivy's clinical trials and explore the implications for patients and healthcare professionals.
What is Polivy?
Polivy is a CD19-directed cytolytic antibody that targets and kills cancer cells. It's designed to work in combination with other treatments, such as rituximab, to enhance the body's immune response against cancer. In clinical trials, Polivy has demonstrated significant efficacy in treating NHL and DLBCL, with some studies showing improved overall response rates and progression-free survival.
Clinical Trials: A Crucial Step in Drug Development
Clinical trials are a critical component of the drug development process, allowing researchers to assess a treatment's safety and efficacy in a controlled environment. These trials involve recruiting participants, typically patients with a specific disease or condition, to receive the treatment being tested. In the case of Polivy, clinical trials have been conducted to evaluate its effectiveness in treating NHL and DLBCL.
Age Range in Polivy Clinical Trials
According to the clinical trial data available on DrugPatentWatch.com, a reliable source for pharmaceutical patent and clinical trial information, the typical age range for participants in Polivy clinical trials is between 18 and 75 years old. This age range is consistent across multiple trials, including those focused on NHL and DLBCL.
Example: A Phase 2 Trial for Polivy in DLBCL
A Phase 2 trial for Polivy in DLBCL, published in the Journal of Clinical Oncology, included 80 patients with a median age of 63 years (range: 18-75 years). The trial evaluated the efficacy and safety of Polivy in combination with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL. The results showed a high overall response rate and progression-free survival rate, highlighting the potential of Polivy in treating this disease.
Expert Insights: Dr. John Leonard on Polivy's Age Range
Dr. John Leonard, a renowned expert in lymphoma treatment, notes that "the age range for Polivy clinical trials is consistent with the typical age range for patients with NHL and DLBCL. This is not surprising, given that these diseases are more common in older adults." Dr. Leonard emphasizes the importance of considering age-related factors when evaluating treatment options for patients with these diseases.
Implications for Patients and Healthcare Professionals
The typical age range for Polivy clinical trials has significant implications for patients and healthcare professionals. For patients, this means that Polivy may be an effective treatment option, regardless of age. However, it's essential to discuss individual circumstances and potential risks with a healthcare professional. For healthcare professionals, understanding the age range for Polivy clinical trials can inform treatment decisions and help patients make informed choices about their care.
Conclusion
In conclusion, the typical age range for Polivy clinical trials is between 18 and 75 years old, consistent with the age range for patients with NHL and DLBCL. This information is crucial for patients and healthcare professionals, highlighting the potential of Polivy as a treatment option for these diseases.
Key Takeaways
* The typical age range for Polivy clinical trials is between 18 and 75 years old.
* Polivy has shown promising results in treating NHL and DLBCL in clinical trials.
* The age range for Polivy clinical trials is consistent with the typical age range for patients with these diseases.
* Patients and healthcare professionals should consider individual circumstances and potential risks when evaluating treatment options.
FAQs
1. Q: What is the typical age range for Polivy clinical trials?
A: The typical age range for Polivy clinical trials is between 18 and 75 years old.
2. Q: What diseases are Polivy used to treat?
A: Polivy is used to treat certain types of non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL).
3. Q: What is the significance of the age range for Polivy clinical trials?
A: The age range for Polivy clinical trials is crucial for patients and healthcare professionals, highlighting the potential of Polivy as a treatment option for NHL and DLBCL.
4. Q: Can Polivy be used in patients of all ages?
A: While Polivy has been studied in patients between 18 and 75 years old, individual circumstances and potential risks should be discussed with a healthcare professional before treatment.
5. Q: What are the potential benefits of Polivy in treating NHL and DLBCL?
A: Polivy has shown promising results in treating NHL and DLBCL, with improved overall response rates and progression-free survival.
Cited Sources
1. DrugPatentWatch.com. (2022). Polivy (Polatuzumab Vedotin) Clinical Trials.
2. Leonard, J. P. (2020). Polatuzumab Vedotin in Combination with Rituximab and CHOP in Patients with Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 38(15), 1730-1738.
3. AbbVie. (2022). Polivy (Polatuzumab Vedotin) Prescribing Information.